Sobi has completed the acquisition of AstraZeneca’s Synagis (palivizumab) for $1.5 billion in cash and shares, plus certain conditional payments. As part of the deal, first announced in August ...

It will compete with Sobi's Synagis (palivizumab), an antibody originated by AZ, which is dosed once a month. Today, AZ and Sanofi revealed the results of a second phase 3 trial – MELODY ...

Respiratory syncytial virus (RSV) is the most important cause of infantile bronchiolitis and pneumonia. It is ubiquitous, with most children acquiring their primary infection within the first year ...

The table is limited by our hospital pharmacy's formulary; however, our purpose was to update the current literature. The table is intended for use as a guide when medications labeled for ...